Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...

Results CF neutrophils live longer due to decreased apoptosis. This was observed in both cystic fibrosis transmembrane conductance regulator (CFTR) null piglets and patients with CF, and furthermore ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

This time, civic group AfriForum is threatening legal action against the Information Regulator, which wants to file an urgent court application to interdict the Department of Basic Education from ...

between the banking regulator and the two biggest managers of index-based mutual funds and exchange-traded funds. The FDIC is pushing both firms to adopt "passivity agreements," which provide the ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

The California Department of Insurance announced Monday that the final step of its regulatory overhaul is in place after more than a year in the works, signifying the largest change in regulations ...

On Friday, the FDIC said it reached a similar deal with Vanguard strengthening the rules the asset manager must observe as a passive investor in FDIC-supervised banks, the latest step in a months-long ...

The commission approved a 2% increase for electricity which is expected to raise $11.9 million more for the company in 2025, and a 7.5% increase in 2026 to raise an extra $44.4 million. Avista had ...